Oncology and Hematology - Global Oncology Academy

177-192 of 743

Evolving Approaches to Early-Onset CRC Detection
Evolving Approaches to Early-Onset CRC Detection
On the Frontlines of Colorectal Cancer
Evolving Approaches to Early-Onset CRC Detection
Peter Buch, MD, FACG, AGAF, FACP
- Peter Buch, MD, FACG, AGAF, FACP
Retifanlimab Across POD1UM-303 Subgroups in Squamous Cell Carcinoma of the Anal Canal
Retifanlimab Across POD1UM-303 Subgroups in Squamous Cell Carcinoma of the Anal Canal
Project Oncology®
Retifanlimab Across POD1UM-303 Subgroups in Squamous Cell Carcinoma of the Anal Canal
Charles Turck, PharmD, BCPS, BCCCP; Marwan G. Fakih, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Marwan G. Fakih, MD
Comparing Photodynamic Therapy Approaches in Basal Cell Carcinoma
Comparing Photodynamic Therapy Approaches in Basal Cell Carcinoma
AudioAbstracts
Comparing Photodynamic Therapy Approaches in Basal Cell Carcinoma
Ryan Quigley
- Ryan Quigley
Closing Gaps in CRC Screening: Patient-Centered Strategies
Closing Gaps in CRC Screening: Patient-Centered Strategies
On the Frontlines of Colorectal Cancer
Closing Gaps in CRC Screening: Patient-Centered Strategies
Peter Buch, MD, FACG, AGAF, FACP
- Peter Buch, MD, FACG, AGAF, FACP
Are E-Cigarettes Safer? A Closer Look at Lung Cancer Risk
Are E-Cigarettes Safer? A Closer Look at Lung Cancer Risk
AudioAbstracts
Are E-Cigarettes Safer? A Closer Look at Lung Cancer Risk
Ryan Quigley
- Ryan Quigley
ESTI Refines Pulmonary Nodule Management in Lung Cancer Screening
ESTI Refines Pulmonary Nodule Management in Lung Cancer Screening
Project Oncology®
ESTI Refines Pulmonary Nodule Management in Lung Cancer Screening
Concurrent Atezolizumab Fails to Improve Survival in Limited-Stage SCLC
Concurrent Atezolizumab Fails to Improve Survival in Limited-Stage SCLC
Project Oncology®
Concurrent Atezolizumab Fails to Improve Survival in Limited-Stage SCLC
Updates in AML Care: Evolving ASH Guidelines for Older Adults
Updates in AML Care: Evolving ASH Guidelines for Older Adults
On the Frontlines of AML/ALL
Updates in AML Care: Evolving ASH Guidelines for Older Adults
Shelina Ramnarine, PhD; Mikkael A. Sekeres, MD, MS
- Shelina Ramnarine, PhD
- Mikkael A. Sekeres, MD, MS
Venetoclax and Palbociclib in AML: Exploring New Findings
Venetoclax and Palbociclib in AML: Exploring New Findings
On the Frontlines of AML/ALL
Venetoclax and Palbociclib in AML: Exploring New Findings
Ryan Quigley; Jeffrey Tyner, PhD
- Ryan Quigley
- Jeffrey Tyner, PhD
- Melissa Stewart, PhD
Advancing Relapse Prediction in Pediatric AML Through Genomic MRD
Advancing Relapse Prediction in Pediatric AML Through Genomic MRD
On the Frontlines of AML/ALL
Advancing Relapse Prediction in Pediatric AML Through Genomic MRD
Ryan Quigley; Amanda Winters, MD, PhD
- Ryan Quigley
- Amanda Winters, MD, PhD
How Early Decisions in Upper GI Cancer Shape Long-Term Outcomes
How Early Decisions in Upper GI Cancer Shape Long-Term Outcomes
Project Oncology®
How Early Decisions in Upper GI Cancer Shape Long-Term Outcomes
Alexandria May, PharmD, BCPS; Sunnie Kim, MD
- Alexandria May, PharmD, BCPS
- Sunnie Kim, MD
Understanding the Growing Burden of Early-Onset CRC
Understanding the Growing Burden of Early-Onset CRC
On the Frontlines of Colorectal Cancer
Understanding the Growing Burden of Early-Onset CRC
Ryan Quigley; Christopher Cann, MD
- Ryan Quigley
- Christopher Cann, MD
Chairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
Chairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
CME/CE
Chairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
Benjamin Levy, MD
0.25 credits
- Benjamin Levy, MD
0.25 credits
Decoding Co-Mutations in HR+, HER2- Metastatic Breast Cancer
Decoding Co-Mutations in HR+, HER2- Metastatic Breast Cancer
On the Frontlines of Metastatic Breast Cancer
Decoding Co-Mutations in HR+, HER2- Metastatic Breast Cancer
Abirami Sivapiragasam
- Abirami Sivapiragasam
Neighborhood Archetypes and Patient Outcomes in Pediatric ALL and AML
Neighborhood Archetypes and Patient Outcomes in Pediatric ALL and AML
On the Frontlines of AML/ALL
Neighborhood Archetypes and Patient Outcomes in Pediatric ALL and AML
Charles Turck, PharmD, BCPS, BCCCP; Lena Winestone, MD, MSHP
- Charles Turck, PharmD, BCPS, BCCCP
- Lena Winestone, MD, MSHP
Assessing G-CSF Prophylaxis with Sacituzumab Govitecan in mTNBC
Assessing G-CSF Prophylaxis with Sacituzumab Govitecan in mTNBC
Project Oncology®
Assessing G-CSF Prophylaxis with Sacituzumab Govitecan in mTNBC
Charles Turck, PharmD, BCPS, BCCCP; Kelly McCann, MD, PhD
- Charles Turck, PharmD, BCPS, BCCCP
- Kelly McCann, MD, PhD
- Gregory Vidal, MD, PhD

12/11